Connecting you to content on EBSCOhost

Works by Eom HS

Results: 5

1

Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling.

Published in:

2010

By:

Yoo BC;
Kong SY;
Jang SG;
Kim KH;
Ahn SA;
Park WS;
Park S;
Yun T;
Eom HS;
Yoo, Byong Chul;
Kong, Sun-Young;
Jang, Sang-Geun;
Kim, Kyung-Hee;
Ahn, Sun-A;
Park, Weon-Seo;
Park, Sohee;
Yun, Tak;
Eom, Hyeon-Seok

Publication type:

journal article

2

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.

Published in:

2009

By:

Sym SJ;
Lee DH;
Kang HJ;
Nam SH;
Kim HY;
Kim SJ;
Eom HS;
Kim WS;
Suh C

Publication type:

Journal Article

3

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.

Published in:

2012

By:

Kang HJ;
Kim WS;
Kim SJ;
Lee JJ;
Yang DH;
Kim JS;
Lee SR;
Lee GW;
Kim HJ;
Kim HY;
Oh SY;
Kim HC;
Eom HS;
Chung J;
Park J;
Suh C;
Ryoo BY

Publication type:

Journal Article

4

Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

Published in:

2012

By:

Won YW;
Kwon JH;
Lee SI;
Oh SY;
Kim WS;
Kim SJ;
Won JH;
Kim KH;
Park SK;
Kim JS;
Suh C;
Yoon DH;
Park JS;
Kim MK;
Kim H;
Kang HJ;
Mun YC;
Kwak JY;
Kim HJ;
Eom HS

Publication type:

Journal Article

5

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Published in:

2012

By:

Kim HJ;
Yoon SS;
Lee DS;
Sohn SK;
Eom HS;
Lee JL;
Chung JS;
Kim K;
Suh C;
Won JH;
Kim JS;
Park JS;
Kang HJ;
Seong CM;
Kim CS;
Lee SJ;
Lee JH

Publication type:

Journal Article